NIAGEN is not a molecule. It is a trademark: a crystal form of nicotinamide riboside chloride, sold by one company and built on intellectual property it licenses. So “NIAGEN vs NMN” is not a contest between two compounds — it is a brand on one side and an unbranded molecule on the other, and what you are really choosing between is two different kinds of uncertainty.
With NIAGEN you know exactly what material is in the capsule and can read the trials run on that material, and nearly all of those trials were paid for by the company selling it. With NMN the trials come from academic groups with nothing to sell, and nothing connects the powder you bought to the powder they used. Which of those bothers you more is the decision.
If what you actually want is the molecule-versus-molecule verdict — is nicotinamide riboside better than NMN — that is a different question and we answer it in NMN vs NR. Neither is an alternative to NAD⁺ itself, either; both convert into it, which is why what NR is is worth five minutes before you shop.
What the brand-named evidence says
NIAGEN is named in the title of its own registration trial, which is rare enough to be useful: an eight-week randomized, double-blind, placebo-controlled study in overweight but otherwise healthy adults gave 100, 300 and 1,000 mg daily and raised whole blood NAD⁺ dose-dependently by 22%, 51% and 142%, within two weeks and sustained for the rest of the study. There were no reports of flushing, no significant difference in adverse events against placebo or between doses, and no elevation of LDL cholesterol [1].
The same paper is where the two regulatory facts that distinguish the brand come from: the crystal form is generally recognized as safe for use in foods, and is the subject of two New Dietary Ingredient Notifications for use in dietary supplements [1]. Those are filings about a specific manufactured material, not about nicotinamide riboside in the abstract, and no generic NR or NMN powder inherits them.
The earlier human pharmacokinetic work is the same story. The first clinical trial of NR pharmacokinetics in humans found dose-dependent increases in the blood NAD⁺ metabolome at 100, 300 and 1,000 mg, and a single-person pilot in which blood NAD⁺ rose as much as 2.7-fold after one oral dose [2].
Both papers carry the disclosure that matters. The registration trial was funded by the manufacturer; two of its three authors are its employees and the third is the inventor of the licensed intellectual property and the company’s chief scientific adviser. The pharmacokinetic paper was sponsored by the same company, which also supplied the NR. None of that makes the numbers wrong. It means the numbers have not been produced by anyone with an incentive to find less.
The independent trial that measured an outcome
It exists, and it is the most useful thing anyone can tell you about this ingredient. An investigator-initiated randomized, placebo-controlled, double-blind trial gave 40 obese, insulin-resistant men (n = 40) nicotinamide riboside at 1,000 mg twice daily for 12 weeks. Insulin sensitivity measured by hyperinsulinemic euglycemic clamp was not improved. Neither was endogenous glucose production, glucose disposal, glucose oxidation, resting energy expenditure, lipolysis, lipid oxidation or body composition. The dose was safe; it simply did not do anything the trial was built to detect [3].
Set the two side by side and the pattern is the one that runs through this entire category: the trials that measured a blood level found a large, clean, dose-dependent effect, and the trial that measured something a person would notice found nothing. Raising NAD⁺ is established. That raising it does anything for you is still not.
What NMN has instead
Independence. The NMN trials were run by university groups with no ingredient to sell, and two of them measured outcomes rather than markers. In postmenopausal women with prediabetes, NMN increased insulin-stimulated glucose disposal measured by clamp, with no change on placebo [4] — the same endpoint, the same method, and the opposite result to the independent NR trial above. In a randomized, double-blind, placebo-controlled dose-ranging trial of 80 healthy middle-aged adults (n = 80), blood NAD rose at 300, 600 and 900 mg daily against both placebo and baseline (all p ≤ 0.001) [5].
What NMN does not have is identity. There is no trademarked crystal form, no GRAS determination and no NDI notification behind the powder in a generic capsule, and its status as a lawful dietary supplement ingredient in the United States is unresolved. So a buyer has published independent trials and no way to establish that the material in front of them resembles the material those trials used — not purity, not stability, not identity. That is the exact gap the brand exists to fill, and it is why people keep paying for it.
What this costs
Less than the category implies, on both sides. Tru Niagen, the consumer brand built on the NIAGEN ingredient, lists $39.20 a month on subscription for a 300 mg daily serving. The oral precursor brands we have verified run from under $20 a month to well over $100, and every price carries the date it was read, on the supplement board with the date attached. Both are a small fraction of what an injection costs for a format with no controlled outcome trials at all. If you land on NMN, the brands differ far more on price per gram than on anything else — ranked here.
How to actually decide
If you want to be able to point at the trials and say “that is the material in my capsule”, buy the branded ingredient and read its funding disclosures with your eyes open. If you would rather have evidence nobody paid for, buy NMN and accept that you cannot verify what you received.
What neither choice buys is the outcome on the label. Both molecules raise NAD⁺ in randomized human trials. Neither has shown that raising it makes a healthy person younger, sharper or more energetic, and a brand name does not change that — it only tells you whose powder failed to prove it.